Nautilus Biotechnology, Inc. (NAUT) SEC Filings & Earnings Calls
EquiReason read 22 Nautilus Biotechnology, Inc. SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-11 — Schedule 13D/A: AH Bio Fund II, L.P. 4.9%.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
11 Sep 20268-K · 1.01, 1.02Nautilus entered into an at-the-market offering agreement with TD Cowen to sell up to $125M of common stock, replacing a prior agreement with no sales. No obligation to sell; shelf registration filed.open
Risks flagged
Potential dilution from future share sales under the ATM program.
“Company may sell shares of common stock from time to time”
11 Sep 2026SC 13D/AAndreessen Horowitz funds sold shares and fell below the 5% beneficial ownership threshold in Nautilus Biotechnology.open
Risks flagged
Insider selling / loss of major investor support
“The Reporting Persons ceased to be the beneficial owners of more than five percent of the Issuer's common stock on September 9, 2026.” · word for word
28 Aug 2026SC 13D/AAndreessen Horowitz funds sold a substantial number of shares in Nautilus Biotechnology, reducing their stake but remaining above 5%.open
Risks flagged
Insider selling / potential loss of major investor support
“The Reporting Persons' beneficial ownership of the Issuer's securities consists of (i) 7,094,691 shares of the Issuer's common stock directly held by AH Bio II for itself and as nominee for AH Bio Fund II-B, L.P. ("AH Bio II-B") and (ii) 590,241 shares of the Issuer's common stock directly held by AH LSV II for itself and as nominee for Andreessen Horowitz L”
28 Jul 202610-QNautilus reported Q2 2026 results: first revenue of $190k, net loss of $14.5M, cash of $84M.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q2-2026 | $-14M | -4% y/y |
| Research and development expense · Q2-2026 | $10M | -8% y/y |
| Selling, general and administrative expense · Q2-2026 | $6M | -6% y/y |
| Cash and cash equivalents · 2026-06-30 | $13M | +6% y/y |
| Short-term investments · 2026-06-30 | $71M | -22% y/y |
| Accumulated deficit · 2026-06-30 | $-361M | +9% y/y |
| Operating cash flow · H1-2026 | $-27M | -2% y/y |
| Net loss per share, basic and diluted · H1-2026 | $-0.23 | -8% y/y |
| Cash, cash equivalents and short-term investments · 2026-06-30 | $84M |
Risks flagged
Broadscale assay development delay
“While our development efforts continue for our broadscale assay, those efforts have not advanced sufficiently to support general availability of that assay in 2027 to our target specifications.” · word for word
Dependence on single source suppliers
“The Company relies on single source suppliers for certain components and materials used in the Nautilus Voyager platform.”
No material revenue expected near-term
“We do not anticipate that these early access activities will result in any material revenue.” · word for word
Need for additional capital
“We expect that we will need to raise additional capital to fund our development and commercialization plans.” · word for word
Supply chain disruptions
“We have, in the past, experienced some supply disruptions, including closures at certain chip manufacturers, which led to extended lead times for certain chips and lower availability of certain reagents.” · word for word
28 Jul 20268-K · 2.02Nautilus reported Q2 2026 results: first revenue of $0.2M, net loss $14.5M, cash $129.2M. Updated roadmap delays broadscale assay but accelerates proteoform applications. No guidance provided.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $200000.00 | |
| Operating expenses · Q2-2026 | $16M | -7% y/y |
| Net loss · Q2-2026 | $15M | -3% y/y |
| Cash, cash equivalents, and investments · 2026-06-30 | $129M |
Risks flagged
Broadscale assay delayed indefinitely; key improvement areas identified but no commercial timeline.
“determined that our assay configuration changes do not sufficiently improve... We plan to report back on a commercial timeline for the Broadscale Assay at a future date.” · word for word
28 Apr 202610-QQ1 2026 results: net loss improved to $14.7M from $16.6M in prior-year quarter; no revenue; cash burn continues.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · Q1-2026 | $15M | -12% y/y |
| Research and Development Expense · Q1-2026 | $10M | -16% y/y |
| Selling, General and Administrative Expense · Q1-2026 | $6M | -12% y/y |
| Cash and Cash Equivalents · 2026-03-31 | $15M | +18% y/y |
| Short-term Investments · 2026-03-31 | $81M | -11% y/y |
| Accumulated Deficit · 2026-03-31 | $347M | +4% y/y |
Risks flagged
Pre-revenue development stage company with no commercial products
“We do not have any products available for commercial sale, and we have not generated any revenue from our Nautilus Voyager platform or other sources since inception.” · word for word
Cash burn and need for additional financing
“The Company will be required to seek additional equity or debt financing to fund future operations, and the Company may not be able to raise it on acceptable terms or at all.” · word for word
Single source supplier dependency
“The Company relies on single source suppliers for certain components and materials used in the Nautilus Voyager platform.”
28 Apr 20268-K · 2.02Pre-revenue biotech reports Q1 2026 net loss of $14.7M, cash $143.4M, operating expenses down 14% YoY. Early Access Program initiated with Baylor College of Medicine. No revenue or guidance.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $15M | -11% y/y |
| Operating expenses · Q1-2026 | $16M | -14% y/y |
| Cash, cash equivalents, and investments · 2026-03-31 | $143M |
Risks flagged
Pre-revenue stage with no commercial product; development and regulatory risks.
“the Nautilus Voyager product platform is not yet commercially available and remains subject to significant scientific and technical development” · word for word
26 Feb 202610-KAnnual report for a development-stage company with no revenue, highlighting platform progress and Early Access Program launch.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents, and investments · FY2025 | $169M |
Risks flagged
Development Stage Risk
“our dependence on the success of our proteomics platform (the “Nautilus Voyager TM platform”), which remains in the development stage and subject to scientific and technical validation” · word for word
No Revenue
“We have incurred net losses in each year since inception and expect to continue to incur net losses for the foreseeable future.”
26 Feb 20268-K · 2.02Pre-revenue biotech reports Q4/FY2025 results: net loss narrowed to $13.8M (Q4) and $59.0M (FY), cash $156.1M, guides FY2026 opex +15-20% YoY, no material revenue expected, cash runway through 2027.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q4-2025 | $14M | -22% y/y |
| Net loss · FY2025 | $59M | -17% y/y |
| Operating expenses · Q4-2025 | $15M | -23% y/y |
| Operating expenses · FY2025 | $67M | -18% y/y |
| Cash, cash equivalents, and investments · 2025-12-31 | $156M |
Guidance
FY2026 operating expenses expected to increase by approximately 15–20% year over year compared to 2025; no material revenue expected from Early Access Program engagements in 2026; cash runway through 2027 based on $156.1M cash.
Pre-revenue company guides opex increase of 15-20% YoY in FY2026; no revenue guidance; cash runway through 2027.
Risks flagged
Pre-revenue stage with no material revenue expected in FY2026; platform not yet commercial; development and commercialization risks.
“In 2026, we do not anticipate material revenue from our Early Access Program engagements.” · word for word
28 Oct 202510-QQuarterly report showing reduced net loss and operating expenses year-over-year for a pre-revenue development-stage company.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, and short-term investments · Q3-2025 | $131M | |
| Net loss · Q3-2025 | $14M | -17% y/y |
| Research and development expenses · Q3-2025 | $10M | -22% y/y |
| Accumulated deficit · Q3-2025 | $318M |
Risks flagged
Development Stage Risk
“our dependence on the success of our proteomics platform (the “Nautilus platform”), which remains in the development stage and subject to scientific and technical validation” · word for word
Going Concern Risk
“The Company has incurred net operating losses and negative cash flows from operations in every year since inception and expects this to continue for the foreseeable future.” · word for word
28 Oct 20258-K · 2.02Pre-revenue biotech reports Q3 2025 results: net loss $13.6M (narrowed from $16.4M), cash $168.5M, early access program expected H1 2026, commercial launch late 2026.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $14M | -17% y/y |
| Operating expenses · Q3-2025 | $16M | -19% y/y |
| Cash, cash equivalents, and investments · 2025-09-30 | $169M |
Risks flagged
Pre-revenue stage; platform not yet commercial; development and commercialization risks.
“Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development.” · word for word
Nautilus Biotechnology, Inc. — questions
- What did Nautilus Biotechnology, Inc. file recently?
- 22 SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-11 — Schedule 13D/A: AH Bio Fund II, L.P. 4.9%
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.